Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Net Cash Flow (2016 - 2025)

Lisata Therapeutics (LSTA) has disclosed Net Cash Flow for 12 consecutive years, with $2.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Net Cash Flow rose 124.49% year-over-year to $2.2 million, compared with a TTM value of -$455000.0 through Sep 2025, up 96.46%, and an annual FY2024 reading of -$6.3 million, up 33.69% over the prior year.
  • Net Cash Flow was $2.2 million for Q3 2025 at Lisata Therapeutics, up from -$3.4 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $8.7 million in Q3 2023 and bottomed at -$9.8 million in Q4 2023.
  • Average Net Cash Flow over 3 years is -$1.2 million, with a median of -$3.2 million recorded in 2024.
  • The sharpest move saw Net Cash Flow crashed 201.85% in 2024, then surged 646.52% in 2025.
  • Year by year, Net Cash Flow stood at -$9.8 million in 2023, then skyrocketed by 66.85% to -$3.2 million in 2024, then surged by 166.8% to $2.2 million in 2025.
  • Business Quant data shows Net Cash Flow for LSTA at $2.2 million in Q3 2025, -$3.4 million in Q2 2025, and $4.0 million in Q1 2025.